Department of O UTCOMES R ESEARCH

20
Department of OUTCOMES RESEARCH

description

Department of O UTCOMES R ESEARCH. Clinical Research Design. Types of Clinical Research Sources of Error Study Design Clinical Trials. Daniel I. Sessler, M.D. Professor and Chair Department of O UTCOMES R ESEARCH The Cleveland Clinic. Case-Control Studies. - PowerPoint PPT Presentation

Transcript of Department of O UTCOMES R ESEARCH

Page 1: Department of  O UTCOMES R ESEARCH

Department of OUTCOMES RESEARCH

Page 2: Department of  O UTCOMES R ESEARCH

Daniel I. Sessler, M.D.Professor and Chair

Department of OUTCOMES RESEARCH

The Cleveland Clinic

Clinical Research Design

Types of Clinical ResearchSources of Error

Study DesignClinical Trials

Page 3: Department of  O UTCOMES R ESEARCH

Case-Control Studies

Identify cases & matched controls

Look back in time and compare on exposure

Time

Case Group

Control Group

Exposure

Page 4: Department of  O UTCOMES R ESEARCH

Cohort StudiesIdentify exposed & matched unexposed patients

Look forward in time and compare on disease

Time

Exposed

Unexposed

Disease

Page 5: Department of  O UTCOMES R ESEARCH

Timing of Cohort Studies

Time

Initial exposures Disease onset or diagnosis

PROSPECTIVE COHORT STUDY

AMBIDIRECTIONAL COHORT STUDY

RETROSPECTIVE COHORT STUDY

Page 6: Department of  O UTCOMES R ESEARCH

Sources of Error

There is no perfect study•All are limited by practical and ethical considerations•It is impossible to control all potential confounders•Multiple studies required to prove a hypothesis

Good design limits risk of false results•Statistics at best partially compensate for systematic error

Major types of error•Selection bias•Measurement bias•Confounding•Reverse causation•Chance

Page 7: Department of  O UTCOMES R ESEARCH

Statistical Association

Page 8: Department of  O UTCOMES R ESEARCH

Selection Bias

Non-random selection for inclusion / treatment•Or selective loss

Subtle forms of disease may be missed

When treatment is non-random:•Newer treatments assigned to patients most likely to benefit•“Better” patients seek out latest treatments•“Nice” patients may be given the preferred treatment

Compliance may vary as a function of treatment•Patients drop out for lack of efficacy or because of side effects

Largely prevented by randomization

Page 9: Department of  O UTCOMES R ESEARCH

Measurement Bias

Quality of measurement varies non-randomly

Quality of records generally poor •Not necessarily randomly so

Patients given new treatments watched more closely

Subjects with disease may better remember exposures

When treatment is unblinded•Benefit may be over-estimated•Complications may be under-estimated

Largely prevented by blinding

Page 10: Department of  O UTCOMES R ESEARCH

Example of Measurement Bias

Reported parental history Arthritis (%) No arthritis (%)

Neither parent 27 50

One parent 58 42

Both parents 15 8

From Schull & Cobb, J Chronic Dis, 1969

P = 0.003

Page 11: Department of  O UTCOMES R ESEARCH

Measurement & Selection Bias

Page 12: Department of  O UTCOMES R ESEARCH

Confounding

Association between two factors caused by third factor

For example, mortality greater in Florida than Alaska•But average age is much higher in Florida•Increased mortality results from age, rather than geography of FL

For example, transfusions associated with mortality•But patients having larger, longer operations require more blood•Increased mortality may be a consequence of larger operations

Largely prevented by randomization

Page 13: Department of  O UTCOMES R ESEARCH

External Threats to Validity

Population of interest

Eligible Subjects

Subjects enrolled

Selection bias

Measurement biasConfounding

Chance

Conclusion

Internal validityExternal validity

???

Page 14: Department of  O UTCOMES R ESEARCH

Study Design

Life is short; do things that matter!•Is the question important?

Is it worth years of your life?

Concise hypothesis testing of important outcomes•Usually only one or two hypotheses per study•Beware of studies without a specified hypothesis

A priori design•Planned comparisons with identified primary outcome•Intention-to-treat design

Randomization•Best prevention for selection bias and confounding•Concealed allocation

– No a priori knowledge of randomization

Page 15: Department of  O UTCOMES R ESEARCH

Subject Selection

Appropriate for question•Maximize incidence of desired outcome•Technically, results apply only to population studied

– Broaden enrollment to improve generalizability

As restrictive as practical; trade-off between:•Variability•Ease of recruitment

Sample-size estimates •Usually from preliminary data•Defined stopping points

Page 16: Department of  O UTCOMES R ESEARCH

Blinding / Masking

Only reliable way to prevent measurement bias•Essential for subjective responses

– Use for objective responses whenever possible

•Careful design required to maintain blinding

Use double blinding whenever possible•Avoid triple blinding!

Maintain blinding throughout data analysis•Even data-entry errors can be non-random•Statisticians are not immune to bias!

Placebo effect can be enormous

Page 17: Department of  O UTCOMES R ESEARCH

Importance of Blinding

Mackey, Personal communication

Chronic Pain

Analgesic

Page 18: Department of  O UTCOMES R ESEARCH

More About Placebo Effect

Kaptchuk, PLoS ONE, 2010

Page 19: Department of  O UTCOMES R ESEARCH

Conclusion: Good Clinical Studies…

Test a specific a priori hypothesis•Evaluate clinically important outcomes

Use appropriate statistical analysis

Make conclusions that follow from the data•And acknowledged substantive limitations

Randomize treatment & conceal allocation if possible•Best protection against selection bias and confounding

Blind patients and investigators if possible•Best protection against measurement bias

Page 20: Department of  O UTCOMES R ESEARCH

Department of OUTCOMES RESEARCH